Key result
Prior to PCI for stable coronary heart disease, 68.6% of patients received at least one lipid-lowering and one symptom-oriented drug, showing conservative therapy is not fully exhausted.
Why the study?
To determine the prescription of guideline-recommended drug therapy in patients with stable coronary heart disease prior to PCI in Germany, and examine regional healthcare and patient factors.
Observational
Yes
Conservative medical therapy options are not fully exhausted prior to PCI in patients with stable coronary heart disease in Germany, indicating room for improvement in guideline adherence.
Suboptimal pre-PCI guideline drug therapy in sCHD shows gaps in routine care; leaves open regional supply influences beyond patient factors.
OBJECTIVES: To determine the prescription of guideline recommended drug therapy in patients with stable coronary heart disease (sCHD) prior to percutaneous coronary intervention (PCI) in Germany and to examine the role of patient characteristics and features of regional healthcare supply in a multilevel model. DESIGN: Secondary data analysis of factors associated with the prescription of guideline recommended drug therapy using a multilevel model to analyse regional-level effects, over and above the effects of patient-level demographic and health status. SETTING: Office-based prescriptions in the year prior to the invasive procedure. PARTICIPANTS: A linked nationwide dataset from Germany's three largest statutory health insurance funds of all patients receiving PCI in the year 2016. MAIN OUTCOME MEASURES: Patients' odds of receiving optimal medical therapy and symptom-oriented therapy within 1 year prior to PCI. RESULTS: 68.6% of patients received at least one lipid-lowering drug and one symptom-oriented therapy prior to PCI. 43.6% received at least two agents to control their symptoms. Patients who received treatment in accordance with the recommendations had a greater number of diagnosed risk factors, a more severe history of cardiac disease and used a higher volume of ambulatory office-based physician services. The prescriptions prevalence for the symptom-oriented therapies differed significantly between eastern and western Germany, with a higher prevalence in the eastern districts. CONCLUSIONS: Guidelines can only provide decision-making corridors, and the applicability of recommendations must always be assessed on a case by case basis. Nevertheless, our analysis indicates that the prevalence of prescriptions in routine practice is subject to substantial variation and that conservative therapy options are not fully exhausted prior to PCI. This suggests that there might be room for improvement in the care of patients with sCHD.
No takes yet. Share an insight, caveat, or question.
Frank-Tewaag et al. (2020) conducted an observational in stable coronary heart disease (sCHD). Guideline-recommended drug therapy was evaluated on Patients' odds of receiving optimal medical therapy and symptom-oriented therapy within 1 year prior to PCI. Prior to PCI for stable coronary heart disease, 68.6% of patients received at least one lipid-lowering and one symptom-oriented drug, showing conservative therapy is not fully exhausted.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: